切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2018, Vol. 12 ›› Issue (09) : 492 -499. doi: 10.3877/cma.j.issn.1674-0785.2018.09.003

所属专题: 乳腺疾病 文献

临床研究

CD44和EPCR mRNA在乳腺癌组织中的表达及其临床意义
罗明华1, 叶静2, 张增2, 金香兰1, 尹为华1,()   
  1. 1. 518036 深圳,北京大学深圳医院病理科
    2. 518036 深圳,北京大学深圳医院中心实验室
  • 收稿日期:2018-04-25 出版日期:2018-05-01
  • 通信作者: 尹为华
  • 基金资助:
    广东省医学科学技术研究基金资助项目(A2017262)

Clinical significance of CD44 and EPCR mRNA expression in breast cancer

Minghua Luo1, Jing Ye2, Zeng Zhang2, Xianglan Jin1, Weihua Yin1,()   

  1. 1. Department of Pathology, Peking University Shenzhen Hospital, Shenzhen 518036, China
    2. Central Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China
  • Received:2018-04-25 Published:2018-05-01
  • Corresponding author: Weihua Yin
  • About author:
    Corresponding author: Yin Weihua, Email:
引用本文:

罗明华, 叶静, 张增, 金香兰, 尹为华. CD44和EPCR mRNA在乳腺癌组织中的表达及其临床意义[J/OL]. 中华临床医师杂志(电子版), 2018, 12(09): 492-499.

Minghua Luo, Jing Ye, Zeng Zhang, Xianglan Jin, Weihua Yin. Clinical significance of CD44 and EPCR mRNA expression in breast cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(09): 492-499.

目的

探讨肿瘤干细胞标记物CD44和EPCR在乳腺癌组织中的相关性及其与乳腺癌临床病理特征的关系。

方法

选取2015年1月至4月在北京大学深圳医院行乳腺癌切除术的46例女性患者,用实时荧光定量RT-PCR(qRT-PCR)检测非特殊型浸润性乳腺癌及其配对癌旁正常乳腺组织中CD44及EPCR的mRNA表达水平,分析其与临床病理特征的关系,并探讨两者的相关性。

结果

(1)荧光定量RT-PCR结果显示CD44 mRNA在乳腺癌组织中的表达明显高于癌旁正常乳腺组织,差异具有统计学意义(t=2.486,P=0.017),在ER阳性乳腺癌明显低于ER阴性组、在正常乳腺样型的三阴型乳腺癌明显高于非正常乳腺样型的三阴型组,差异具有统计学意义(t=-2.332,P=0.024;t=-4.209,P<0.01),但与患者年龄、肿瘤大小、组织学分级、淋巴结转移及临床分期无关(P>0.05);(2)EPCR mRNA在乳腺癌组织中的表达明显高于癌旁正常乳腺组织,差异具有统计学意义(t=4.028,P<0.01),与乳腺癌的肿瘤大小(t=2.998,P<0.01)、组织学分级(t=4.082,P<0.01)、淋巴结转移(t=2.152,P=0.037)、临床分期(t=-2.378,P=0.022)、ER(t=-5.585,P<0.01),PR(t=-3.896,P<0.01)及增殖指数Ki67(t=2.197,P=0.033)相关,差异具有统计学意义。但与患者的年龄及HER2无关(P>0.05),在三阴型(尤其是基底样型)乳腺癌及Luminal B型乳腺癌中的相对表达水平也明显高于非三阴型组及非Luminal B型组,差异具有统计学意义(t=9.163,P<0.01;t=3.653,P=0.003);(3)在乳腺癌中,CD44及EPCR mRNA的表达呈显著正相关(rs=0.540,P<0.01)。

结论

乳腺癌干细胞标志物CD44及EPCR在乳腺癌组织中均明显表达上调,2者具有正相关,但EPCR与更多的临床病理特征相关,提示EPCR可更好地预测乳腺癌的淋巴结转移及较高临床分期等不良预后,并推测CD44及EPCR可能所标记为2种不同表型的乳腺癌干细胞。

Objective

To detect the expression of the stem cell markers CD44 and EPCR in breast cancer and analyze their correlation with clinicopathological parameters.

Methods

Quantitative real-time PCR (qRT-PCR) was performed to measure the expression of CD44 and EPCR mRNAs in invasive breast carcinoma of no special type (IBC-NST) tissues and matched normal breast tissues from 46 women.

Results

The expression level of CD44 mRNA was significantly higher in IBC-NST than in adjacent normal tissues (t=2.486, P=0.017), in ER- IBC-NST than in ER+ IBC-NST tissues (t=-2.332, P=0.024), and in normal breast-like triple negative IBC-NST than in non-normal breast-like triple negative IBC-NST tissues(t=-4.209, P<0.01). However, there was no significant correlation between CD44 expression and patient age, tumor size, histological grade, clinical stage, or lymph node metastasis (P>0.05). The expression level of EPCR mRNA in IBC-NST tissues was significantly higher than that in adjacent normal tissues (t=4.028, P<0.01). The expression of EPCR mRNA was significantly related to tumor size (t=2.998, P<0.01), histological grade (t=4.082, P<0.01), lymph node metastasis (t=2.152, P=0.037), clinical stage (t=-2.378, P=0.022), ER status (t=-5.585, P<0.01), PR status (t=-3.896, P<0.01), and Ki-67 index (t=2.197, P=0.033), but not to patient age and HER-2 status (P>0.05). In addition, the expression level of EPCR mRNA was significantly higher in triple negative (especially basal-like subtype) than in non-triple negative tissues (t=9.163, P<0.01), and in luminal B IBC-NST than in non-luminal B IBC-NST tissues (t=9.163, P<0.01; t=3.653, P=0.003). There was a positive correlation between CD44 and EPCR mRNA expression (rs=0.540, P<0.01).

Conclusion

The expression of the stem cell markers CD44 and EPCR in breast cancer is significantly higher and positively correlated in IBC-NST, but the expression of EPCR is associated with more clinicopathological features, suggesting that EPCR can better predict lymph node metastasis and a poor prognosis in breast cancer. It is speculated that CD44 and EPCR may represent respective markers of two different types of breast cancer stem cells.

图1 46例乳腺癌组织中CD44的表达相对于配对癌旁正常组织的表达情况
表1 CD44的表达与非特殊型浸润性乳腺癌患者临床病理特征的关系(±s
表2 CD44mRNA的表达与乳腺癌分子亚型的关系
图2 46例乳腺癌组织中EGFR的表达相对于配对癌旁正常组织的表达情况
表3 EPCR的表达与非特殊型浸润性乳腺癌患者临床病理特征的关系
表4 EPCRmRNA的表达与乳腺癌分子亚型的关系
1
Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001, 414(6859):105-111.
2
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100(7):3983-3988.
3
Sheridan C, Kishimoto H, Fuchs RK, et al.CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis[J]. Breast Cancer Res, 2006, 8(5):R59.
4
Ginestier C, Hur MH, Charafe-Jauffret E, et al.ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1(5):555-567.
5
Huang YH, Luo MH, Ni YB, et al. Increased SOX2 expression in less differentiated breast carcinomas and in lymph node metastases[J]. Histopathology, 2014, 64(4):494-503.
6
Wright MH, Caleagno AM, Saleido CD, et a1. Brcal breast tumor contain distinct CD44/CD24 and CD133 cells with cancer stem cell characteristics[J]. Breast Cancer Res, 2008, 10(1):R10.
7
Tsang JY, Huang YH, Luo MH, et al. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer[J]. Breast Cancer Res Treat, 2012, 136(2):407-417.
8
Ramalho-Santos M, Yoon S, Matsuzaki Y, et al. Stemness: transcriptional profiling of embryonic and adult stem cells[J]. Science, 2002, 298(5593):597-600.
9
Ivanova NB, Dimos JT, Schaniel C, et al. A stem cell molecular signature[J]. Science, 2002, 298(5593):601-604.
10
Blanpain C, Lowry WE, Geoghegan A, et al.Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche[J]. Cell, 2004, 118(5):635-648.
11
Wang D, Cai C, Dong X, et al. Identification of multipotent mammary stem cells by protein C receptor expression[J]. Nature, 2015, 517(7532):81-84.
12
Shipitsin M, Campbell LL, Argani P, et a1. Molecular definition of breast tumor heterogeneity[J]. Cancer Cell, 2007, 11(3):259-273.
13
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol. 2010, 28(16):2784-95.
14
Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update[J]. J Clin Oncol, 2018, 36(20):2105-2122.
15
Hwang-Verslues WW, Kuo WH, Chang PH, et al. Multiple Lineages of Human Breast Cancer Stem/Progenitor Cells Identified by Profiling with Stem Cell Markers[J]. PLoS One, 2009 4(12):e8377.
16
Petäjä J. Inflammation and coagulation. An overview[J]. Thromb Res, 2011, 127(Suppl 2):34-37.
17
罗明华,尹为华,陈耀丽, 等. EPCR在乳腺癌的表达及其预后意义[J]. 临床与实验病理学杂志, 2018, 34(5):408-412.
18
Wang D, Liu C, Wang J, et al. Protein C Receptor stimulates multiple signaling pathways in breast cancer cells[J]. J Biol Chem, 2018, 293(4):1413-1424.
19
Wise R, Zolkiewska A. Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway[J]. Breast Cancer Res Treat, 2017, 166(2):421-433.
20
章青波,卢玫瑰,徐宝福, 等. 乳腺浸润性导管癌中的表达及其临床意义[J].临床与实验病理学杂志, 2017, 33(7):724-727.
21
de Beça FF, Caetano P, Gerhard R, et a1. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types[J]. J Clin Pathol, 2013, 66(3):187-191.
22
Yan Q, Xiaorong Z, Zhang Z, et al. Prevalence of protein C receptor (PROCR) is associated with inferior clinical outcome in Breast invasive ductal carcinoma[J]. Pathol Res Pract, 2017, 213(9):1173-1179.
23
Zeng YA, Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture[J]. Cell Stem Cell, 2010, 6(6):568-577.
24
Yi XJ, Zhao YH, Xiao LX, et a1. Abrrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with osteosarcoma side population cells of high tumorrigenicity[J]. Mol Med Rep, 2015, 12(4):5042-5048.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要